Horizon Therapeutics Public Lim HZNP Stock
Horizon Therapeutics Public Lim Price Chart
Horizon Therapeutics Public Lim HZNP Financial and Trading Overview
Horizon Therapeutics Public Lim stock price | 116.3 USD |
Previous Close | 100.62 USD |
Open | 100.7 USD |
Bid | 0 USD x 1100 |
Ask | 0 USD x 800 |
Day's Range | 100.59 - 101.51 USD |
52 Week Range | 57.84 - 113.83 USD |
Volume | 2M USD |
Avg. Volume | 2.28M USD |
Market Cap | 23.16B USD |
Beta (5Y Monthly) | 1.112323 |
PE Ratio (TTM) | 63.71698 |
EPS (TTM) | 0 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 116.5 USD |
HZNP Valuation Measures
Enterprise Value | 23.37B USD |
Trailing P/E | 63.71698 |
Forward P/E | 14.768221 |
PEG Ratio (5 yr expected) | 3.78 |
Price/Sales (ttm) | 6.477241 |
Price/Book (mrq) | 4.544476 |
Enterprise Value/Revenue | 6.537 |
Enterprise Value/EBITDA | 33.961 |
Trading Information
Horizon Therapeutics Public Lim Stock Price History
Beta (5Y Monthly) | 1.112323 |
52-Week Change | 22.75% |
S&P500 52-Week Change | 20.43% |
52 Week High | 113.83 USD |
52 Week Low | 57.84 USD |
50-Day Moving Average | 106.02 USD |
200-Day Moving Average | 95.2 USD |
HZNP Share Statistics
Avg. Volume (3 month) | 2.28M USD |
Avg. Daily Volume (10-Days) | 1.61M USD |
Shares Outstanding | 228.62M |
Float | 226.28M |
Short Ratio | 2.19 |
% Held by Insiders | 1.17% |
% Held by Institutions | 98.96% |
Shares Short | 7.27M |
Short % of Float | 3.20% |
Short % of Shares Outstanding | 3.18% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 10.39% |
Operating Margin (ttm) | 18.56% |
Gross Margin | 77.08% |
EBITDA Margin | 19.24% |
Management Effectiveness
Return on Assets (ttm) | 4.67% |
Return on Equity (ttm) | 7.50% |
Income Statement
Revenue (ttm) | 3.58B USD |
Revenue Per Share (ttm) | 15.62 USD |
Quarterly Revenue Growth (yoy) | -6.00000000000000000000000000000000% |
Gross Profit (ttm) | 2.8B USD |
EBITDA | 688.27M USD |
Net Income Avi to Common (ttm) | 371.9M USD |
Diluted EPS (ttm) | 1.59 |
Quarterly Earnings Growth (yoy) | -73.20% |
Balance Sheet
Total Cash (mrq) | 2.31B USD |
Total Cash Per Share (mrq) | 10.11 USD |
Total Debt (mrq) | 2.68B USD |
Total Debt/Equity (mrq) | 52.64 USD |
Current Ratio (mrq) | 4.072 |
Book Value Per Share (mrq) | 22.293 |
Cash Flow Statement
Operating Cash Flow (ttm) | 1.13B USD |
Levered Free Cash Flow (ttm) | 900.27M USD |
Profile of Horizon Therapeutics Public Lim
Country | United States |
State | N/A |
City | Dublin |
Address | 70 St. Stephen’s Green |
ZIP | 2 |
Phone | 353 1 772 2100 |
Website | https://www.horizontherapeutics.com |
Industry | Drug Manufacturers-General |
Sector(s) | Healthcare |
Full Time Employees | 2145 |
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
Q&A For Horizon Therapeutics Public Lim Stock
What is a current HZNP stock price?
Horizon Therapeutics Public Lim HZNP stock price today per share is 116.3 USD.
How to purchase Horizon Therapeutics Public Lim stock?
You can buy HZNP shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Horizon Therapeutics Public Lim?
The stock symbol or ticker of Horizon Therapeutics Public Lim is HZNP.
Which industry does the Horizon Therapeutics Public Lim company belong to?
The Horizon Therapeutics Public Lim industry is Drug Manufacturers-General.
How many shares does Horizon Therapeutics Public Lim have in circulation?
The max supply of Horizon Therapeutics Public Lim shares is 0.
What is Horizon Therapeutics Public Lim Price to Earnings Ratio (PE Ratio)?
Horizon Therapeutics Public Lim PE Ratio is 0.00000000 now.
What was Horizon Therapeutics Public Lim earnings per share over the trailing 12 months (TTM)?
Horizon Therapeutics Public Lim EPS is 0 USD over the trailing 12 months.
Which sector does the Horizon Therapeutics Public Lim company belong to?
The Horizon Therapeutics Public Lim sector is Healthcare.
Horizon Therapeutics Public Lim HZNP included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 17601.05 USD — |
+0.87
|
8.38B USD — | 17181.27 USD — | 17716.52 USD — | — - | 8.38B USD — |
NASDAQ Q 50 NXTQ | 795.02 USD — |
+1.44
|
— — | 775.23 USD — | 798.39 USD — | — - | — — |
NASDAQ Global Select Market Com NQGS | 8613.57 USD — |
+0.85
|
— — | 8409.7 USD — | 8670.37 USD — | — - | — — |
Nasdaq Next Generation 100 Inde NGX | 1190.09 USD — |
+1.39
|
— — | 1160.42 USD — | 1194.59 USD — | — - | — — |
NASDAQ Biotechnology NBI | 4209.36 USD — |
+1.85
|
— — | 4100.47 USD — | 4211.44 USD — | — - | — — |
NASDAQ HealthCare IXHC | 942.47 USD — |
+1.43
|
— — | 920.56 USD — | 943.62 USD — | — - | — — |
NASDAQ Composite Total Return I XCMP | 21542.13 USD — |
+0.87
|
— — | 21028.39 USD — | 21683.46 USD — | — - | — — |
Nasdaq US Smart Pharmaceuticals NQSSPH | 1438.45 USD — |
+1.08
|
— — | 1414.44 USD — | 1439.08 USD — | — - | — — |
NASDAQ DM Ex Japan Large Mid Ca NQDMXJPLMAUD | 2100.38 AUD 1390.15 USD |
<0.01
|
— — | 2100.38 AUD 1390.15 USD | 2100.38 AUD 1390.15 USD | — - | — — |
Stlmt ID NASDAQ Biotechnology NBX | 4486.38 USD — |
-0.37
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
NASDAQ Biotechnology Total Retu XNBI | 4554.45 USD — |
+1.85
|
— — | 4436.63 USD — | 4556.71 USD — | — - | — — |
- {{ link.label }} {{link}}